Step by step: Lilly sets its course to reduce, replace, offset
Our purpose is to make life better. Our employees and our society now demand that this mission very clearly includes protecting and preserving the world we live in. That’s why we set out our ESG goals and invest in projects like the solar farm.
Speaking at the July opening of Lilly’s new solar panel farm in Ireland, Taoiseach (Prime Minister) Micheál Martin described it as a “first class project”, one which represents the sort of “dramatic change” that is needed across Europe today. The 16-acre site was developed with renewable energy experts Enerpower and is the largest of its kind in Ireland. But as Lilly chairman and CEO Dave Ricks commented, the solar farm at our Kinsale manufacturing site represents one element of Lilly’s push for carbon neutrality by 2030.
Ambitious targets to help make life better
Lilly’s bread-and-butter work is discovering medicines and developing treatments that improve people’s lives. It makes no sense to undermine that positive impact by negatively impacting the environment, so Lilly is also aiming to reach ambitious environmental, social and governance goals (ESGs).
Making medicines requires the use of valuable resources, including energy, water and raw materials. So, in addition to carbon neutrality in all our operations by 2030, we’re committed to reducing waste and improving water security across the life cycles of our products and our supply chain.
The road to sustainability is not a straightforward one. It will require a lot of creative initiatives, big and small, local and international in scale. The Kinsale solar farm is a flagship project indicative of the step-by-step approach – “the most spectacular evidence of that commitment,” as described by Todd Winge, Vice President and General Manager of Lilly Kinsale.
Local impact
The solar panel farm now helps power a significant proportion of the Irish Lilly manufacturing campus. 12,500 individual solar panels, all linked together, stretch across three fields and allow Lilly to reduce the use of electricity from carbon sources by almost 6 gigawatt hours (GWh) per year. This, the largest solar farm in the country, translates to an annual carbon footprint reduction of 2,350 tonnes.
The staff who live and work in and around the Kinsale site take great pride in the fact that, despite having grown tremendously in size over the past 40 years, it remains sensitive to the local surroundings and community. The solar project is no different. Local wildlife has not been disturbed, sheep can be seen roaming around among the panels, and plans are underway to add beehives in the fields, aimed at enhancing biodiversity in the area.
Projects such as this demonstrate the possibilities of effective local investment. Small but meaningful contributions can increase the production of clean energy without taking resources from the local community.
A model for change
Our purpose is to make life better. Our employees and our society now demand that this mission very clearly includes protecting and preserving the world we live in. We all must do our part to embody sustainability and reduce, replace and offset where we can. That’s why we set out our ESG goals and invest in projects like the solar farm.
As we look to our global leaders to advance climate commitments at COP26, companies across all sectors must take actions such as these to increase their energy efficiency. It is our hope that the Kinsale solar farm will inspire others to make similar, meaningful investments. In fact one of our next projects is a large solar development in Strasbourg, France, that aims to replicate Kinsale’s success.
Tags in this Article:
No categories
Related articles
Europe's medicines ecosystem: how can it be reshaped for the benefit of patients?
As the EU emerges from the pandemic, the next steps of the European Commission’s Pharmaceutical Strategy will define the EU’s future as a global leader in pharmaceuticals – or not. Marcel Lechanteur, President Lilly France, Benelux and EU Affairs, shares his views on how the medicines ecosystem in Europe can be reshaped for the benefit of patients.
Ten hurdles to patient access to new medicines
Of all track and field events, the hurdles is the most nail-biting. A magnificent athlete at the peak of their powers can be several metres ahead of the rest … yet fail at the final hurdle and finish last. The delayed Tokyo Olympics will hopefully take place later this year, and I’ll be following the exploits of the great Spanish 110-meter hurdler, Orlando Ortega, with both excitement and trepidation.
PRIME TIME: Reflecting on the first 5 years of the EMA’s PRIority MEdicines scheme
It's hard to fathom that five years have passed since the European Medicines Agency (EMA) adopted the PRIority MEdicine (PRIME) scheme. In March 2016, PRIME was received with high expectations for greater speed of access for patients in Europe. On this five-year anniversary, I’d like to offer several reflections on PRIME from the viewpoint of one innovative pharmaceutical company that has not had a PRIME-designated product to date.